US-based Acutis Diagnostics, a specialised clinical and biosciences company, announced on Tuesday that it has named Dr Abdel Halim as its new chief scientific officer and executive vice president for biopharma and diagnostics services.

Dr Halim has more than 25 years of experience. He has headed biomarker, diagnostic and precision medicine aspects in 150 plus phase 1 to phase three clinical trials belonging to 40 plus development programs with contributions to clinical trial design, conduct, analysis and interpretation. He has served on over 20 CLSI committees to create clinical and laboratory guidelines and authored 12 of them. He is accredited by the FDA as a third-party reviewer of 510k submissions.

In the new role, Dr Halim is to offer scientific leadership to advance clinical product development, cancer genomics and biopharma services.